This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yagi, H. Articles by Seo, N. Search for Related Content PubMed PubMed Citation Articles by Yagi, H. Articles by Seo, N.

Induction of Therapeutically Relevant Cytotoxic T Lymphocytes in Humans by Percutaneous Peptide Immunization

¹ Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan and ² Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Requests for reprints: Hiroaki Yagi, Department of Dermatology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan. Phone: 81-53-435-2303; Fax: 81-53-435-2368; E-mail: hiroyagi{at}hama-med.ac.jp.

Percutaneous peptide immunization (PPI) is a simple and noninvasive immunization approach to induce potent CTL responses by peptide delivery via skin with the stratum corneum removed. After such a barrier disruption in human skin, epidermal Langerhans cells, although functionally matured through the up-regulation of HLA expression and costimulatory molecules, were found to emigrate with a reduced number of dendrites. CD8⁺ populations binding to MHC-peptide tetramers/pentamers and producing IFN- appeared in the blood after PPI with HLA class I–restricted antigenic peptides. PPI with melanoma-associated peptides reduced the lesion size and suppressed further development of tumors in four of seven patients with advanced melanoma. These beneficial effects were accompanied by the generation of circulating CTLs with in vitro cytolytic activity and extensive infiltration of tetramer/pentamer-binding cells into regressing lesions. PPI elicited neither local nor systemic toxicity or autoimmunity, except for vitiligo, in patients with melanoma. Therefore, PPI represents a novel therapeutic intervention for cancer in the clinical setting. (Cancer Res 2006; 66(20): 10136-44)

This article has been cited by other articles:

				A. Vogt, B. Mahe, D. Costagliola, O. Bonduelle, S. Hadam, G. Schaefer, H. Schaefer, C. Katlama, W. Sterry, B. Autran, et al. Transcutaneous Anti-Influenza Vaccination Promotes Both CD4 and CD8 T Cell Immune Responses in Humans J. Immunol., February 1, 2008; 180(3): 1482 - 1489. [Abstract] [Full Text] [PDF]

				P. Stoitzner, L. K. Green, J. Y. Jung, K. M. Price, C. H. Tripp, B. Malissen, A. Kissenpfennig, I. F. Hermans, and F. Ronchese Tumor Immunotherapy by Epicutaneous Immunization Requires Langerhans Cells J. Immunol., February 1, 2008; 180(3): 1991 - 1998. [Abstract] [Full Text] [PDF]